Published in Gut on March 02, 2012
Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir. Aliment Pharmacol Ther (2013) 2.15
Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients. Hepatology (2015) 1.55
Evidence-based consensus on the diagnosis, prevention and management of hepatitis C virus disease. World J Hepatol (2015) 0.86
Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3. World J Gastroenterol (2014) 0.83
Metabolic factors and chronic hepatitis C: a complex interplay. Biomed Res Int (2013) 0.82
Modulation of host lipid metabolism by hepatitis C virus: Role of new therapies. World J Gastroenterol (2015) 0.80
Current level of evidence on causal association between hepatitis C virus and type 2 diabetes: A review. J Adv Res (2016) 0.79
Are metabolic factors still important in the era of direct antiviral agents in patients with chronic hepatitis C? World J Gastroenterol (2013) 0.78
Individualization of chronic hepatitis C treatment according to the host characteristics. World J Gastroenterol (2014) 0.78
The influence of the brain-derived neurotropic factor Val66Met genotype and HMG-CoA reductase inhibitors on insulin resistance in the schizophrenia and bipolar populations. Clin Transl Sci (2012) 0.77
Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. World J Gastroenterol (2016) 0.77
Metabolic syndrome in chronic hepatitis C infection: does it still matter in the era of directly acting antiviral therapy? Hepat Med (2014) 0.77
Inhibition of IRS-1 by hepatitis C virus infection leads to insulin resistance in a PTEN-dependent manner. Virol J (2015) 0.76
Insulin resistance and steatosis in HBV-HCV co-infected patients: Role of PNPLA3 polymorphisms and impact on liver fibrosis progression. World J Hepatol (2014) 0.76
Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection. World J Hepatol (2017) 0.75
Diabetes mellitus, insulin resistance and hepatitis C virus infection: A contemporary review. World J Gastroenterol (2017) 0.75
Insulin resistance and response to telaprevir plus pegylated interferon and ribavirin: a requiem for the HOMA score? Gastroenterology (2012) 0.75
Hepatitis C virus induces a pre-diabetic state by directly impairing hepatic glucose metabolism in mice. J Biol Chem (2017) 0.75
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med (2004) 16.21
Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med (2011) 12.09
Telaprevir for retreatment of HCV infection. N Engl J Med (2011) 10.48
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med (2009) 10.21
HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med (2008) 9.75
Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med (2004) 9.72
Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med (2010) 8.40
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med (2014) 8.13
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med (2005) 7.18
A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med (2006) 6.31
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med (2014) 6.31
Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology (2005) 5.93
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med (2003) 5.79
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol (2013) 5.64
Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol (2008) 4.21
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med (2003) 4.19
Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med (2003) 4.12
Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med (2014) 4.09
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology (2006) 3.92
Noninvasive assessment of liver fibrosis. Hepatology (2010) 3.86
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology (2006) 3.80
Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol (2004) 3.80
Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology (2007) 3.61
Features associated with success rate and performance of FibroScan measurements for the diagnosis of cirrhosis in HCV patients: a prospective study of 935 patients. J Hepatol (2006) 3.57
Influence of the timing of cardiac surgery on the outcome of patients with infective endocarditis and stroke. Clin Infect Dis (2012) 3.49
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med (2005) 3.46
Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial. Ann Intern Med (2009) 3.41
Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Liver Transpl (2006) 3.29
Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol (2005) 3.27
Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology (2014) 3.23
Hospital admission is a relevant source of hepatitis C virus acquisition in Spain. J Hepatol (2007) 3.21
Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology (2006) 3.19
Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology (2004) 3.19
Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology (2004) 3.19
An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med (2014) 3.04
Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology (2009) 3.02
Activated intestinal macrophages in patients with cirrhosis release NO and IL-6 that may disrupt intestinal barrier function. J Hepatol (2013) 2.98
Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology (2009) 2.97
Early features of acute-on-chronic alcoholic liver failure: a prospective cohort study. Gut (2010) 2.91
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology (2010) 2.81
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int (2011) 2.77
Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy. Hepatology (2013) 2.64
Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study. J Hepatol (2008) 2.63
Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology (2006) 2.62
Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load. Hepatology (2013) 2.60
Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology (2014) 2.56
Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology (2003) 2.54
Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes. Hepatology (2012) 2.49
Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology (2010) 2.48
Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology (2013) 2.46
Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat Rev Drug Discov (2004) 2.46
TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother (2009) 2.44
Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol (2010) 2.43
Second hepatitis C replication compartment indicated by viral dynamics during liver transplantation. J Hepatol (2005) 2.39
Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2009) 2.33
Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. J Hepatol (2002) 2.30
Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology (2006) 2.26
Occult infection of peripheral B cells by hepatitis C variants which have low translational efficiency in cultured hepatocytes. Gut (2010) 2.25
Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. Hepatology (2002) 2.21
Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology (2006) 2.21
World Gastroenterology Organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Clin Gastroenterol (2014) 2.17
Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol (2007) 2.16
Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology (2002) 2.15
Chemoembolization for hepatocellular carcinoma: 1-month response determined with apparent diffusion coefficient is an independent predictor of outcome. Radiology (2013) 2.12
HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology (2008) 2.11
Keratin 19: a key role player in the invasion of human hepatocellular carcinomas. Gut (2013) 2.10
Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology (2013) 2.08
Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology (2006) 2.07
Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology (2007) 2.07
Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure. J Hepatol (2012) 2.05
Effect of gender and ITPA polymorphisms on ribavirin-induced anemia in chronic hepatitis C patients. J Hepatol (2013) 2.04
Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology (2006) 2.03
Endoscopic resection of ampullary lesions: a single-center 8-year retrospective cohort study of 91 patients with long-term follow-up. Surg Endosc (2013) 2.01
Resistance profile of darunavir: combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses (2008) 2.01
Evaluation of liver fibrosis: concordance analysis between noninvasive scores (APRI and FIB-4) evolution and predictors in a cohort of HIV-infected patients without hepatitis C and B infection. Clin Infect Dis (2011) 1.97
Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology (2005) 1.97
The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology (2012) 1.97
Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology (2006) 1.97
IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol (2011) 1.97
Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology (2007) 1.95
Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology (2008) 1.95
Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. Hepatology (2002) 1.94
Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS (2009) 1.93
Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med (2007) 1.92
No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology (2010) 1.92
Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr (2006) 1.87
Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. J Hepatol (2011) 1.86